CAS: 159989-64-7; (3S,4As,8As)-N-(Tert-Butyl)-2-((2R,3R)-2-Hydroxy-3-(3-Hydroxy-2-Methylbenzamido)-4-(Phenylthio)Butyl)Decahydroisoquinoline-3-Carboxamide

该化合物是主要用于治疗艾滋病毒感染的抗逆转录病毒药物,属于抑制艾滋病毒蛋白酶,从而防止病毒发芽和复制的一类蛋白抑制剂,Nelfinavir的特点是化学结构,包括独特的苯基和氟化素,有助于其药理活动.该物质通常通过口服进行,并因其相对有利的副作用特征而闻名于其他抗逆转录病毒药物,尽管它仍可造成肠胃紊乱和代谢变化.Nelfinavir经常与其他抗逆转录病毒剂一起使用,以提高其功效和降低抗药性发展的风险.其药性受到食品摄入等因素的影响,可以增强其吸收能力.虽然它曾经是艾滋病毒疗法的基石,但随着新药剂的出现,其使用却有所下降,这些药效和方便性得到了提高.然而,在某些治疗制度中,特别是在资源有限的环境中,它仍然是一个重要的选择.

结构式图片

上下游产品

thiophenol (3S,4aS,8aS)-N-tert-butyl-2-((R)-2-hydroxy-2-((S)-2-(3-hydroxy-2-methylphenyl)-4,5-dihydrooxazol-4-yl)ethyl)-decahydroisoquinoline-3-carboxamide 3-acetoxy-2-methylbenzoyl chloride (2R,3R)-4-((3S,4aS,8aS)-3-(tertbutylcarbamoyl)°Ctahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(phenylthio)butan-2-aminium benzoatenelfinavir mesylate

合成工艺路线路线简述

    2-甲基-3-乙酰氧基苯甲酸置于盐酸,1-羟基苯并三唑,盐酸-N-乙基-N'-(3-二甲氨基丙基)碳二亚胺,三乙胺,对甲苯磺酰氯体系中,用 甲醇 用作溶剂,化学反应 3.0H,反应生成奈非那韦
    参考文献:A Short Synthesis Of The Hiv-Protease Inhibitor Nelfinavir Via A Diastereoselective Addition Of Ammonia To The α,β-Unsaturated Sulfoxide Derived From ( R )-Glyceraldehyde Acetonide
    标题:A Short Synthesis Of The Hiv-Protease Inhibitor Nelfinavir Via A Diastereoselective Addition Of Ammonia To The α,β-Unsaturated Sulfoxide Derived From ( R )-Glyceraldehyde Acetonide
    摘要:Diastereoselective Michael Addition Of Ammonia To Sulfoxide 3A Derived From (R)-Glyceraldehyde Acetonide Provides Amine 4A,Which Is Converted Into Nelfinavir Using (Bf3Et2O)-Et-./nal Reduction And Subsequent Coupling Reactions As Key Steps. (C) 2002 Elsevier Science Ltd. All Rights Reserved.
    Doi:10.1016/s0040-4039(02)02077-4

    海关参考信息

    专利信息


    专利号:US-7173059-B2
    优先权日:2003-05-08
    标题:Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same
    发明人:ALBIZATI KIM FRANCIS; BABU SRINIVASAN
    权利人:AGOURON PHARMA
    摘要:Optically active 3-amino-butene and 1,2-dihydroxy-3-amino-butane intermediate compounds, useful in the synthesis of HIV-protease inhibitors and methods of preparing these intermediate compounds are disclosed.

    专利号:US-6472534-B2
    优先权日:1999-10-21
    标 题:Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
    发明人:BORER BENNETT C; ZOOK SCOTT E; BUSSE JULIETTE K
    权利人:AGOURON PHARMA
    摘要:Methods for the preparation of chemical intermediates in the synthesis of HIV-protease inhibitors related to and including nelfinavir mesylate are disclosed. The method of this invention comprises converting tetrohydran derivatives into oxazolines to provide key reaction intermediates for the preparation of nelfinavir. Also disclosed is a method for the preparation of a chiral amino alcohol from an epoxy-tetrahydrofuran.

    专利号:US-8987493-B2
    优先权日:2010-05-20
    标题 :Process for synthesis of silane dipeptide analogs
    发明人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN
    权利人:SIEBURTH SCOTT MCNEILL; BO YINGJIAN; Temple University—Of the Commonwealth System of Higher Education
    摘要:The invention provides a method of preparing silane dipeptide analogs, comprising the steps of treating a solution of a substituted 1,2-oxasilolane with lithium metal to form a solution of the dilithium salt of a substituted 3-hydroxypropylsilanol, and reacting the solution of the dilithium salt of the substituted 3-hydroxypropylsilanol with a substituted enamine.

    专利号:US-2010261876-A1
    优先权日:2007-09-25
    标 题:Novel methods of synthesis for therapeutic antiviral peptides
    发明人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E
    权利人:BRAY BRIAN L; JOHNSTON BARBARA E; SCHNEIDER STEPHEN E; TVERMOES NICOLAI A; ZHANG HUYI; FRIEDRICH PAUL E
    摘要:Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.

    专利号:US-2025206743-A1
    优先权日:2022-03-25
    标 题:Tyk2 inhibitor synthesis and intermediates thereof
    发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
    权利人:TAKEDA PHARMACEUTICALS CO
    摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.

    专利号:US-11845970-B2
    优先权日:2016-01-15
    标 题:Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
    发明人:WANG LAI-XI; YANG QIANG; LI TIEZHENG; TONG XIN
    权利人:UNIV MARYLAND
    摘要:The present invention provides for recombinant Endo-S2 mutants (named Endo-S2 glycosynthases) that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a fucosylated or nonfucosylated GlcNAc-IgG acceptor. As such, the present invention allows for the synthesis and remodeling of therapeutic antibodies thereby providing for certain biological activities, such as, prolonged half-life time in vivo, less immunogenicity, enhanced in vivo activity, increased targeting ability, and/or ability to deliver a therapeutic agent.
    南通嘉星泰生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.jxtbio.com
    企业联系电话:18795782766;13773776703👤
    📞南通嘉星泰生物科技有限公司 ⚠️参考联系方式
    联系人:蔡先生
    电话:18795782766;13773776703

    传真:0513-87503981
    邮箱:297962169@qq.com
    通信地址: 江苏省如皋市石庄镇张扬园村十组42号
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省如皋市石庄镇张扬园村十组42号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    中国厦门迈克化学进出口有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.mchem.net
    电话: 0592-2218988👤
    📞中国厦门迈克化学进出口有限公司 ⚠️参考联系方式

    销售电话:0592-2218988
    邮箱:admin@mchem.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Nagao Y, Hisanaga T, Utsumi T, Egami H, Kawato Y, Hamashima Y. Enantioselective Synthesis of Nelfinavir via Asymmetric Bromocyclization of Bisallylic Amide. J Org Chem. 2018 Mar 1. doi: 10.1021/acs.joc.8b00039. [Epub ahead of print] doi: 10.1002/art.40326. Epub 2017 Dec 8. doi: 10.1038/leu.2017.212. Epub 2017 Jul 5.
    5: Sato A, Asano T, Okubo K, Isono M, Asano T. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress. Oncol Res. 2018 Mar 5;26(2):323-332. doi: 10.3727/096504017X14957929842972. Epub 2017 May 26. doi: 10.2147/OTT.S136484. eCollection 2017.
    7: Dunlop EA, Johnson CE, Wiltshire M, Errington RJ, Tee AR. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. Oncotarget. 2017 Jul 25;8(30):48711-48724. doi: 10.18632/oncotarget.16232.

    合成参考文献


    参考文献:10.2165/11319380-000000000-00000
    摘要:Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010 Mar 01;33(3):171–87. doi: 10.2165/11319380-000000000-00000.
    参考文献:10.4103/0971-6866.80354
    摘要:Shankarkumar U, Shankarkumar A, Ghosh K. Human immunodeficiency virus therapeutics and pharmacogenomics. Indian J Hum Genet. 2011 May;17 Suppl 1():S22–6.
    参考文献:10.2174/1874613601105010059
    摘要:Álvarez Díaz H, Mariño Callejo A, García Rodríguez JF. Non-Cirrhotic Portal Hypertension in Human Immunodeficiency Virus-Infected Patients: A New Challenge in Antiretroviral Therapy Era. TOAIDJ. 2011 Jun 29;05(1):59–61. doi: 10.2174/1874613601105010059.
    参考文献:10.2174/156800911796798913
    摘要:Bruning A, Vogel M, Mylonas I, Friese K, Burges A. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets. 2011 Sep;11(7):799–809. doi: 10.2174/156800911796798913.
    参考文献:10.1097/qai.0b013e31822b4edc
    摘要:Ellis GM, Huang S, Hitti J, Frenkel LM; P1022 Study Team. Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. J Acquir Immune Defic Syndr. 2011 Nov 01;58(3):241–7.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知